Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Jun 04, 2022 7:25pm
217 Views
Post# 34732027

RE:RE:RE:Difficult-to-value$-TLT...

RE:RE:RE:Difficult-to-value$-TLT...
CancerSlayer wrote:

 

thadeush wrote: Excellent points. I'm no health expert, but I'd imagine the patients TLT is currently treating after other treatments did not cure/help, from wildbird1's points 3, 4, and 5, are already immunocompromised because they are exhausted from the side effects of previous treatment regimens. Yet T:T is still getting excellent results. Imagine the results TLT will get when they finally have the chance to be the first line of treatment and can make use of a patient's more robust immune response. Methinks it will improve their percentages significantly.

 

 

If TLT's higher efficacy & safety rates pan out at completion of the study, I'd also expect there will be some off-label use of TLT's ACT as a first line option, especially considering our protocol requires only two treatments.  

One would expect a push for earlier use of our ACT when you consider the high failure rate of BCG in high-risk NMIBC (recurrence & significant 5 year risk of progression) & the fact that roughly 60+% of patients with NMIBC don't even receive adequate BCG therapy due to various factors, including adverse events, side effects, poor compliance/too many treatments, limited BCG supply, cost, etc....these factors become even more of an issue when treating higher-risk NMIBC (i.e. CIS disease), which can require significantly more treatments/bladder instillations (up to a total of 30+ treatments over several years).  And if/once our ACT is approved & the word gets out, I wouldn't be surprised to see such off-label use continue to increase over time due to both increasing doctor & "patient" demand.

If all goes well, I also expect our ACT will be involved in various 1st/2nd-line combo trials (w/BCG & others) to validate its benefits beyond being a stand-alone option in the most severe/refractory cases.

 


 

Forgot to mention...in addition to entering future combo trials, I anticipate there will eventually be much broader investigation of our ACT in the form of more extensive randomized clinical trials, comparing our ACT as a potential first-line option against the standard of care....but we can leave that expense to our future partner or Pharma ; ).  All of the above JMHO.

<< Previous
Bullboard Posts
Next >>